# NeuroVista

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurovista

- Industry: Medical Devices & Equipment
- Headquarters: Seattle, US
- Website: www.neurovista.com
- Total disclosed funding: $50M
- Latest round: Series C (Aug 18, 2010)
- Investors on record: 6

## About

NeuroVista is a healthcare technology company specializing in innovative neurological monitoring solutions, aiming to enhance patient care and treatment outcomes for neurological disorders.Founded in 2004 in Seattle, US, NeuroVista focuses on developing advanced monitoring systems for individuals with neurological conditions. The company was founded by Emil Koch, who has a history of entrepreneurial ventures in the tech sector. NeuroVista has successfully raised a total of USD 16.50 mn across multiple funding rounds, with the latest round being a Venture Debt round amounting to USD 5.00 mn, backed by Cyberonics, Inc.NeuroVista operates primarily in the healthcare sector, providing advanced neurological monitoring solutions that allow for real-time data collection and analysis. Their products are designed to improve the management and treatment of neurological disorders, catering to patients and healthcare providers. The service aims to enhance clinical decision-making through reliable data, ultimately improving patient outcomes.Revenue generation for NeuroVista is derived from the sale of their neurological monitoring systems and associated services. The firm's business model includes direct-to-consumer and partnerships with healthcare facilities, with pricing structured around the specific needs of healthcare providers. The financial performance closely aligns with the volume of technology deployed across various healthcare settings, reflecting the demand for innovative neurological solutions.NeuroVista is currently developing new products to expand its range of neurological monitoring technologies, with planned launches expected in the upcoming year. The company is targeting expansion into international markets, specifically focusing on Europe and Asia by 2025, to reach a broader patient population. The recent funding of USD 5.00 mn will support these initiatives, enabling further research and development while enhancing their market presence.

## Funding rounds

- Series C, Aug 18, 2010, $17M — Advanced Technology Ventures, Delphi Ventures, Foundation Medical Partners, GBS Venture Partners
- Series B, May 11, 2007, $34M — Advanced Technology Ventures, Delphi Ventures, Sprout Group, Foundation Medical Partners, Three Arch Partners

## Investors

- Advanced Technology Ventures (https://capitalatlas.ai/funds/advanced-technology-ventures) — Series B, Series C
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series B, Series C
- Sprout Group (https://capitalatlas.ai/funds/sprout-group) — Series B
- Foundation Medical Partners (https://capitalatlas.ai/funds/foundation-medical-partners) — Series B, Series C
- Three Arch Partners (https://capitalatlas.ai/funds/three-arch-partners) — Series B
- GBS Venture Partners (https://capitalatlas.ai/funds/gbs-venture-partners) — Series C